(Q38631586)

4 September 2017

Optimizing the diagnosis and the treatment of iron overload diseases (English)

1 reference

4 September 2017

1 reference

Pierre Brissot

1

1 reference

4 September 2017

11 November 2015

1 reference

Expert Review of Gastroenterology & Hepatology

4 September 2017

1 reference

4 September 2017

10

1 reference

4 September 2017

3

1 reference

4 September 2017

359-370

1 reference

Iron metabolism and related genetic diseases: A cleared land, keeping mysteries

4 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Iron disorders of genetic origin: a changing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Diagnosis and treatment of hereditary hemochromatosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Iron-overload-related disease in HFE hereditary hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Increased height in HFE hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Non-HFE hemochromatosis: pathophysiological and diagnostic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

21 January 2018

Iron deficiency anaemia

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Iron therapy in chronic kidney disease: Recent changes, benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

The pathophysiology of transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Iron overload in non-transfusion-dependent thalassemia: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Systemic iron homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Identification of erythroferrone as an erythroid regulator of iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Erythroferrone contributes to recovery from anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Non-transferrin bound iron: a key role in iron overload and iron toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Aceruloplasminemia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Advances in metal-induced oxidative stress and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

LPI-labile plasma iron in iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

The liver: conductor of systemic iron balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Hemochromatosis and alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

21 January 2018

Reply: To PMID 25605615.

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Second round robin for plasma hepcidin methods: first steps toward harmonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Estimating tissue iron burden: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Impact of iron assessment by MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Non-invasive assessment of hepatic iron stores by MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Hepatic iron concentration and total body iron stores in thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Treatment of nongout joint deposition diseases: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Miscellaneous non-inflammatory musculoskeletal conditions. Haemochromatosis: the bone and the joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Iron chelation: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Manipulation of the hepcidin pathway for therapeutic purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Protein antioxidants in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2016.1119043

10.1586/17474124.2016.1119043

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26561304